Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment
Durva/Treme may be effective and safe for patients with u-HCC, even in patients who receive Durva/Treme as a later-line treatment.
Authors
- Tamami Abe (ORCID: https://orcid.org/0000-0001-8314-7187)
- Hiroki Sato (ORCID: https://orcid.org/0000-0002-6994-1840)
- Akiko Suzuki (ORCID: https://orcid.org/0000-0003-3163-8093)
- Keisuke Kakisaka (ORCID: https://orcid.org/0000-0001-9627-138X)
- Kei Sawara (ORCID: https://orcid.org/0000-0003-4608-277X)
- Yudai Fujiwara (ORCID: https://orcid.org/0009-0000-9569-3273)
- Hidekatsu Kuroda (ORCID: https://orcid.org/0000-0002-1471-1087)
- Kenji Yusa (ORCID: https://orcid.org/0000-0001-8484-2288)
- Akio Miyasaka (ORCID: https://orcid.org/0000-0001-7747-5977)
- Tomoaki Nagasawa (ORCID: https://orcid.org/0000-0002-4386-3223)
- Ippeki Nakaya
- Kei Endo (ORCID: https://orcid.org/0000-0002-9698-2779)
- Takuya Watanabe (ORCID: https://orcid.org/0000-0003-4795-674X)
- Yuichi Yoshida (ORCID: https://orcid.org/0000-0002-7025-7675)
- Takayuki Matsumoto (ORCID: https://orcid.org/0000-0001-9786-3854)
- Takayoshi Oikawa (ORCID: https://orcid.org/0000-0002-1100-6980)
- Asami Ito
Institutions
- Iwate Medical University (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s40801-024-00458-7
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.48